Jubilant Pharmova subsidiary partnered with Ocugen to produce Covaxin for US and Canada markets


On Tuesday, 15th June 2021, the drug company ‘Jubilant Pahrmova’ said, its subsidiary has made a partnership with the US-based company Ocugen Inc. to produce the ‘Covaxin’ corona virus vaccine for the markets of the United States and Canada. Jubilant HollisterStier LLC, which is a step-down subsidiary of the company, has now successfully entered into a manufacturing partnership with the company Ocugen Inc., for the production of the Covaxin corona virus vaccine developed by Bharat Biotech.

In May 2021, both the companies have agreed to expand their agreement for the purpose of commercializing the Covxin jab in the country of Canada, and the company said, they have been very much pleased for partnering Ocugen Inc. and providing support to the ongoing fight against the novel corona virus across the world.

Pramod Yadav, who is the CEO of Jubilant Pharma said that, with the help of the two facilities in the region of North America, that are working to produce multiple corona virus vaccines and therapies, the are going to remain committed for supporting the efforts to eradicate the global corona virus pandemic.

READ  Research shows, Drinking Tea can Reduce Risk of Heart Diseases, Diabetes, and Death

JP Gabriel, senior vice president of Ocugen Inc., said, they have been fully committed to bring the Covaxin covid-19 vaccine to the markets of United States and Canada due to the potential of the vaccine for saving the lives of the people by the addition of a weapon to the fight against the emerging mutated novel corona virus variants across the world, and he also said that, securing the production capability based in United States has been a critical step, which the company is preparing to submit the regulatory submissions to the Health Canada and FDA.